Marta Larrayoz
Overview
Explore the profile of Marta Larrayoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin-Otal C, Sanchez-Moreno I, Gomez-Moron A, Castro C, Casares N, Navarro F, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39988346
Background: Phosphatidylserine (PS) exposed on apoptotic cells promotes immune clearance of dead cells without inducing inflammation. Conversely, PS exposure on live tumor cells promotes an immunosuppressive tumor microenvironment that hinders...
2.
Staudt S, Nikolka F, Perl M, Franz J, Leblay N, Leblay N, et al.
bioRxiv
. 2024 Sep;
PMID: 39314273
The microbiome is a complex host factor and key determinant of the outcome of antibody-based and cellular immunotherapy. Its postbiotics are a blend of soluble commensal byproducts that are released...
3.
Botta C, Perez C, Larrayoz M, Puig N, Cedena M, Termini R, et al.
Nat Commun
. 2023 Sep;
14(1):5825.
PMID: 37730678
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of...
4.
Larrayoz M, Garcia-Barchino M, Celay J, Etxebeste A, Jimenez M, Perez C, et al.
Nat Med
. 2023 Mar;
29(3):632-645.
PMID: 36928817
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry...
5.
Rodriguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino M, et al.
Sci Adv
. 2022 Jan;
8(3):eabl4644.
PMID: 35044826
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the...
6.
Valencia K, Sainz C, Bertolo C, de Biurrun G, Agorreta J, Azpilikueta A, et al.
Dis Model Mech
. 2021 Dec;
15(1).
PMID: 34870316
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell carcinoma (LUSC). We have generated and characterized two models of phenotypically different transplantable...
7.
Fresquet V, Garcia-Barchino M, Larrayoz M, Celay J, Vicente C, Fernandez-Galilea M, et al.
Cancer Discov
. 2020 Dec;
11(5):1268-1285.
PMID: 33355179
For millions of years, endogenous retroelements have remained transcriptionally silent within mammalian genomes by epigenetic mechanisms. Modern anticancer therapies targeting the epigenetic machinery awaken retroelement expression, inducing antiviral responses that...
8.
Blakemore S, Clifford R, Parker H, Antoniou P, Stec-Dziedzic E, Larrayoz M, et al.
Leukemia
. 2020 Feb;
34(7):1760-1774.
PMID: 32015491
Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes....
9.
Wojdacz T, Amarasinghe H, Kadalayil L, Beattie A, Forster J, Blakemore S, et al.
Blood Adv
. 2019 Aug;
3(16):2474-2481.
PMID: 31434681
Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes (IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to chemoimmunotherapy (CIT). DNA methylation profiling can subdivide early-stage patients into...
10.
Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, et al.
Haematologica
. 2018 Sep;
104(2):360-369.
PMID: 30262567
Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately...